Brevetti

Astratto: La presente invenzione si colloca nel settore dei dispositivi medici, e più in particolare riguarda un dispositivo impiantabile passivo per la stimolazione elettrica cardiaca, privo di batterie e di elettrocateteri.

Astratto: gene HMBS

Astratto: Metodo per la determinazione dell'attività somatotropa.

Astratto: Compounds of the general formula (I) and (II) (including formulae (III) to (V)), wherein X - -CH2-, -O-, -S- n = 0-10 Y = -NH-, -NHSO2-, -NHSO-, -NHCO-, -S-, -O-, -CH=CH- R1-R7, equal or different can be hydrogen, alkyl C1-C4, alkenyl C2-C4, cycloalkyl C3-C7, aryl or heteroaryl; may be substituted with one or more alkyl C1-C4, alkoxyl C1-C4, alkylthio C1-C4 or halogens; -NR8R9, where R8 e R9, equal or different, represent hydrogen, alkyl C1-C4, alkenyl C2-C4, cycloalkyl C3-C7, aryl or heteroaryl, may be substituted with one or more C1-C4, alkoxyl C1-C4, alkylthio C1-C4 or halogens; -(CH2)n,-COOR10, with n' = 0-4 and R3 = hydrogen or alkyl C1-C4, and their addition salts with organic and inorganic acids, or alkaline and alkaline earth metal or ammonium ions, with the exclusion of the compounds having the following formulae ((VI) to (IX)).

Astratto: Both type 1 (DMT1) and type 2 (DMT2) diabetes mellitus are characterized by the slow loss of the insulin-producing beta cells in the pancreas and by a long preclinical stage when diagnosis and preventive therapies are already possible. Our inventors identified a novel DMT1 auto-antigen which is selectively expressed by beta cells and likely involved in the control of their progressive death. The identified molecules represent novel targets or tools for the development of diagnostic tests and cytoprotective therapies for diabetes mellitus.

Astratto: The present invention finds application in the field of medicine and, in particular, to new compounds and pharmaceutical preparations containing them useful for the treatment and/or prevention of heart failure

Astratto: La presente invenzione riguarda sonde e l'uso di dette essendo in un metodo diagnostico per rilevare la presenza di Porfiria, in particolare per rilevare la quantità allelica dei geni relativi alla Porfiria.

Astratto: The invention concerns the use of chromogranin A, its peptidic derivatives and their non-peptidic peptidomimetic derivatives in the treatment and prevention of inflammatory pathologies of the digestive system, in the treatment and/or prevention of diseases such as Crohn's disease, ulcerative colitis and, more generally, chronic bowel disease and inflammatory diseases of the respiratory system.

Astratto: The invention concerns the use of chromogranin A, its peptidic derivatives and their non-peptidic peptidomimetic derivatives in the treatment and prevention of inflammatory pathologies of the digestive system, in the treatment and/or prevention of diseases such as Crohn's disease, ulcerative colitis and, more generally, chronic bowel disease and inflammatory diseases of the respiratory system.